Literature DB >> 16801409

Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.

Helio S Sader1, Thomas R Fritsche, Ronald N Jones.   

Abstract

A total of 207 Staphylococcus aureus strains, including 105 well-characterized strains with decreased susceptibility to vancomycin (17 vancomycin-intermediate S. aureus [VISA] and 88 heteroresistant VISA [hVISA] strains) and 102 wild-type methicillin-resistant S. aureus (MRSA-WT) strains were tested by reference/standardized broth microdilution and disk diffusion methods, as well as by Etest (AB BIODISK, Solna, Sweden), against daptomycin and vancomycin. The lowest concentration of antimicrobial agent that killed > or = 99.9% of the initial inoculum was defined as the minimum bactericidal concentration (MBC) endpoint, and time-kill curves were performed in selected strains to further evaluate bactericidal activity. All MRSA-WT and hVISA strains were inhibited by < or = 1 microg/ml of daptomycin, while the VISA strains showed slightly higher daptomycin MICs (range, 0.5 to 4 microg/ml). All daptomycin MBC results were at the MIC or twofold higher. In contrast, 14.7% of MRSA-WT, 69.3% of hVISA, and all VISA strains showed a vancomycin MBC/MIC ratio of > or = 32 or an MBC of > or = 16 microg/ml (tolerant). The correlation coefficients between broth microdilution and disk diffusion method results were low for daptomycin (0.07) and vancomycin (0.11). Eight (3.8%) strains (all hVISA or VISA) were "nonsusceptible" to daptomycin by broth microdilution methods but susceptible by the disk diffusion method. For vancomycin, 35 (16.9%) strains were nonsusceptible by broth microdilution methods but susceptible by disk diffusion methods. In conclusion, daptomycin was highly bactericidal against S. aureus strains, and its bactericidal activity was not affected by decreased susceptibility to vancomycin. In contrast, many (one in seven) contemporary MRSA-WT, the majority of hVISA, and all VISA strains showed vancomycin MBC/MIC ratios consistent with tolerance, a predictor of poor clinical response. Disk diffusion tests generally failed to detect strains categorized as nonsusceptible to daptomycin or vancomycin by the reference broth microdilution method or Etest, and reassessment of breakpoints should be immediately attempted for MIC methods suggested as the test of choice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16801409      PMCID: PMC1489799          DOI: 10.1128/AAC.01491-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.

Authors:  P M Small; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections.

Authors:  Alejandro Domenech; Sandra Ribes; Carmen Cabellos; M Angeles Domínguez; Abelardo Montero; Josefina Liñares; Javier Ariza; Francesc Gudiol
Journal:  Microb Drug Resist       Date:  2004       Impact factor: 3.431

3.  Glycopeptide tolerance in Staphylococcus aureus.

Authors:  J May; K Shannon; A King; G French
Journal:  J Antimicrob Chemother       Date:  1998-08       Impact factor: 5.790

4.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.

Authors:  Sowjanya S Mohan; Brian P McDermott; Burke A Cunha
Journal:  Heart Lung       Date:  2005 Jan-Feb       Impact factor: 2.210

6.  Vancomycin-resistant Staphylococcus aureus--New York, 2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-04-23       Impact factor: 17.586

7.  Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations.

Authors:  V Gopal; A L Bisno; F J Silverblatt
Journal:  JAMA       Date:  1976-10-04       Impact factor: 56.272

8.  Serious staphylococcal infections with strains tolerant to bactericidal antibiotics.

Authors:  A E Denny; L R Peterson; D N Gerding; W H Hall
Journal:  Arch Intern Med       Date:  1979-09

9.  Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination.

Authors:  L Cantoni; M P Glauser; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

10.  Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages.

Authors:  Robin A Howe; Alastair Monk; Mandy Wootton; Timothy R Walsh; Mark C Enright
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

View more
  20 in total

1.  Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007.

Authors:  Maria M Traczewski; Bradley D Katz; Judith N Steenbergen; Steven D Brown
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

2.  Metallo-β-lactamase-producing bacteroides species can shield other members of the gut microbiota from antibiotics.

Authors:  Usha Stiefel; Mary Ann Tima; Michelle M Nerandzic
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

3.  Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates.

Authors:  Mandy Wootton; Alasdair P MacGowan; Timothy R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

4.  Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Authors:  Ronda L Akins; Bradley D Katz; Catherine Monahan; Dylan Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

5.  Penetration of daptomycin into bone and synovial fluid in joint replacement.

Authors:  D Montange; F Berthier; G Leclerc; A Serre; L Jeunet; M Berard; P Muret; L Vettoretti; J Leroy; B Hoen; C Chirouze
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

6.  Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Kara B Mascitti; Paul H Edelstein; Neil O Fishman; Knashawn H Morales; Andrew J Baltus; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2011-12-20       Impact factor: 3.254

Review 7.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.

Authors:  Jason A Crompton; Donald S North; MinJung Yoon; Judith N Steenbergen; Kenneth C Lamp; Graeme N Forrest
Journal:  J Antimicrob Chemother       Date:  2010-06-16       Impact factor: 5.790

9.  Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005.

Authors:  Edward O Mason; Linda B Lamberth; Wendy A Hammerman; Kristina G Hulten; James Versalovic; Sheldon L Kaplan
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

10.  Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.

Authors:  Thomas P Lodise; Ben Lomaestro; Jeffrey Graves; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.